Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 30 min 2 sec ago

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

7 hours 30 min ago
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced that it will hold an investor conference call at 10:30 a.m. Eastern time on Thursday, January 4, 2018. Dial-in instructions will be issued prior to the date of the call. The purpose of the conference call will be to provide investors with an update on the Company’s initiatives and strategic plans, including its capital reorganization, its

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar

Fri, 15/12/2017 - 18:00
INCHEON, South Korea--(BUSINESS WIRE)--#Celltrion--Celltrion's Herzuma receives positive opinion from EMA's CHMP for early breast cancer, metastatic breast cancer, and metastatic gastric cancer

CanniMed Therapeutics Inc. Receives Municipal Approval from Carp Lake Township to Apply for State of Michigan Licenses for Medical Cannabis Production and Processing

Thu, 14/12/2017 - 17:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Receives Approval from Carp Lake Township to Apply for State of Michigan Licenses for Medical Cannabis Production and Processing

Cerveau Technologies, Inc. Signs Research Agreement with KU Leuven University, Belgium

Thu, 14/12/2017 - 16:00
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced an agreement with the KU Leuven university in Belgium to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, i

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

Thu, 14/12/2017 - 09:00
CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc. brings over 45 years of contract development and manufacturing

Jecure Therapeutics Strengthens Management Team

Thu, 14/12/2017 - 09:00
SAN DIEGO, Calif.--(BUSINESS WIRE)--Jecure Therapeutics, a biotechnology company with novel drug discovery programs targeting non-alcoholic steatohepatitis (NASH) and fibrosis, today announced that Gretchen Bain, Ph.D., has joined the company as its Vice President of Biology. Dr. Bain is an accomplished biologist with more than fifteen years of experience in both biotech and pharmaceutical companies. She has deep expertise in the development of small-molecule drug candidates and has directed pr

Grobo Inc. Awarded Top Home Growing Box at 2017 Canadian Cannabis Awards

Thu, 14/12/2017 - 08:00
WATERLOO, Ontario--(BUSINESS WIRE)--#C45--Grobo Inc Awarded Top Home Growing Box at 2017 Canadian Cannabis Awards

OBIO CAAP Companies Raise More Than $109 Million in Investments

Wed, 13/12/2017 - 09:00
TORONTO--(BUSINESS WIRE)--#healthscience--OBIO announces that CAAP companies have raised more than $109 million since program launch in 2013.

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

Tue, 12/12/2017 - 17:00
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

Cyclenium Pharma Announces Drug Discovery Collaboration Agreement with Ono Pharmaceutical

Tue, 12/12/2017 - 08:00
MONTREAL--(BUSINESS WIRE)--#biobucks--Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, announced today the signing of a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd., a leading Japanese pharmaceutical research and development company. The collaboration will exploit Cyclenium’s proprietary QUEST Library™ of next generation synthetic small-molecule m

Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index

Mon, 11/12/2017 - 17:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI), which will become effective prior to market open on Monday, December 18, 2017. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchm

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

Mon, 11/12/2017 - 09:00
RIDGEFIELD, Conn. & INGELHEIM, Germany--(BUSINESS WIRE)--2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring inn

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

Sun, 10/12/2017 - 11:00
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Sun, 10/12/2017 - 09:00
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday,

Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL

Sat, 09/12/2017 - 15:00
SEATTLE--(BUSINESS WIRE)--Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL

Dr. Nancy Braverman: Champion of the AmorChem KNOCK OUT!

Fri, 08/12/2017 - 15:00
QUEBEC CITY, Quebec--(BUSINESS WIRE)--#AmorChem2--The Contenders of the fourth AmorChem KNOCK OUTTM Event valiantly climbed into the ring and duked it out against a panel of Heavyweight Champions for a chance of winning a coveted $500,000 financing from AmorChem. Earlier in the fall, AmorChem, the innovative venture capital seed fund, launched a province-wide call for proposals to participate in its KNOCK OUT Event. All the Contenders displayed remarkable courage and agility in the ring, yet only one could

Bertin and Zymo Research Announce New Collaboration

Thu, 07/12/2017 - 13:00
IRVINE, Calif. & ROCKVILLE, Md.--(BUSINESS WIRE)--#microbiome--Bertin’s Precellys Evolution Homogenizer & Zymo Research’s ZymoBIOMICS Microbial Community Standard: Liberation of DNA From all Microbes in Just 1 min.

Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China

Thu, 07/12/2017 - 12:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has entered into a License and Research Agreement with Shenzhen BioScien Pharmaceuticals Co. Ltd. www.BioScien.cn to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including

Life Sciences Ontario Announces Recipients of 2018 LSO Awards

Thu, 07/12/2017 - 09:00
TORONTO--(BUSINESS WIRE)--LSO today announced the recipients of its 2018 LSO Awards, recognizing outstanding contributions to Ontario’s life sciences sector.

Acerus Appoints Mr. Mark Lievonen to its Board of Directors

Thu, 07/12/2017 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Mr. Mark Lievonen to its Board of Directors. The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors. Mr. Lievonen has also been appointed to the Audit Committee and will serve as its Chair. Mark Lievonen has over 30 years of experience in the pharmaceutical industry, more recently as the President of Sanofi Pasteur Limited, the Canadian vacc

Pages